Search

Displaying results 7161 - 7170 of 8974 in total
  1. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  2. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  3. Drug

    GSK-239512

    go.drugbank.com/drugs/DB15120
    Investigational

    GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).

  4. Drug

    TPMPA

    go.drugbank.com/drugs/DB16754
    Experimental

    [A245308,A245313] TPMPA is used as a pharmacological probe for the investigation of GABA<sub>C</sub> receptor function.[A245313] … TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a selective antagonist of GABA<sub>C</sub> receptors (also known as GABA-ρ or GABA<sub>A-ρ</sub> receptors).

  5. Drug

    MCC

    go.drugbank.com/drugs/DB05282
    Investigational

    MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension.

  6. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  7. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tum...

  8. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  9. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]

  10. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).